AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 187 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $38,940 | +46.4% | 1,375 | +18.7% | 0.01% | +25.0% |
| Q1 2023 | $26,599 | -18.2% | 1,158 | 0.0% | 0.00% | -20.0% |
| Q4 2022 | $32,517 | -1.5% | 1,158 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $33,000 | +26.9% | 1,158 | 0.0% | 0.01% | +25.0% |
| Q2 2022 | $26,000 | -23.5% | 1,158 | 0.0% | 0.00% | -20.0% |
| Q1 2022 | $34,000 | +13.3% | 1,158 | +25.3% | 0.01% | +25.0% |
| Q4 2021 | $30,000 | -30.2% | 924 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $43,000 | -85.9% | 924 | -83.3% | 0.01% | -85.4% |
| Q2 2021 | $305,000 | +6.6% | 5,531 | 0.0% | 0.04% | -4.7% |
| Q1 2021 | $286,000 | +51.3% | 5,531 | +26.6% | 0.04% | +43.3% |
| Q4 2020 | $189,000 | +721.7% | 4,369 | +551.1% | 0.03% | +650.0% |
| Q3 2020 | $23,000 | +27.8% | 671 | +99.7% | 0.00% | 0.0% |
| Q2 2020 | $18,000 | +50.0% | 336 | 0.0% | 0.00% | +33.3% |
| Q1 2020 | $12,000 | – | 336 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |